Top

Pathology & Oncology Research

Published in:

01-07-2015 | Letter to Editor

Frameshift Mutations of TAF7L Gene, a Core Component for Transcription by RNA Polymerase II, in Colorectal Cancers

Authors: Hye Rim Oh, Chang Hyeok An, Nam Jin Yoo, Sug Hyung Lee

Published in: Pathology & Oncology Research | Issue 3/2015

Excerpt

To the Editor: …

Gegonne A, Devaiah BN, Singer DS (2013) TAF7: traffic controller in transcription initiation. Transcription 4:29–33CrossRefPubMedCentralPubMed

Kloet SL, Whiting JL, Gafken P, Ranish J, Wang EH (2012) Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene transcription by TFIID subunits TAF1 and TAF7. Mol Cell Biol 32:3358–3369CrossRefPubMedCentralPubMed

Fukuchi J, Hiipakka RA, Kokontis JM, Nishimura K, Igarashi K, Liao S (2004) TATA-binding protein-associated factor 7 regulates polyamine transport activity and polyamine analog-induced apoptosis. J Biol Chem 279:29921–29929CrossRefPubMed

Yazarloo F, Shirkoohi R, Mobasheri MB, Emami A, Modarressi MH (2013) Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern. Med Oncol 30:368CrossRefPubMed

Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680CrossRefPubMed

Yoo NJ, Kim HR, Kim YR, An CH, Lee SH (2012) Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 60:943–952CrossRefPubMed

Je EM, Kim MR, Min KO, Yoo NJ, Lee SH (2012) Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer 131:E1044–E1047CrossRefPubMed

Title: Frameshift Mutations of TAF7L Gene, a Core Component for Transcription by RNA Polymerase II, in Colorectal Cancers
Authors: Hye Rim Oh
Chang Hyeok An
Nam Jin Yoo
Sug Hyung Lee
Publication date: 01-07-2015
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9832-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2015

FOXC2 Expression is Associated with Tumor Proliferation and Invasion Potential in Oral Tongue Squamous Cell Carcinoma

Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index

A critical Analysis of the Relationship Between Aldehyde dehydrogenases-2 Glu487Lys Polymorphism and Colorectal Cancer Susceptibility

The Role of MRI in the Assessment of the Local Status of Anal Carcinomas and in Their Management

Strong Expression of HBME-1 Associates with High-Risk Clinicopathological Factors of Papillary Thyroid Carcinoma

Thyroid Cancer in Egypt: Histopathological Criteria, Correlation With Survival and Oestrogen Receptor Protein Expression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer